ArticleNature communications2025
Convergence of plasmid-driven virulence and antibiotic resistance in Escherichia coli.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Review
- Comparative genomics of carbapenem resistance and virulence associated with respiratory tract and bloodstream infections in carbapenem-resistantVirulence · 2026Article
- A Biological Approach to Antimicrobial Resistance in New and Old Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2026Review
- Multidrug resistance, biofilm formation, and pathotype diversity of Escherichia coli isolated from diarrheic lambs in intensive sheep farms, Aksu, Xinjiang, China.BMC microbiology · 2026Article
- Molecular epidemiology reveals distinct lineages and genomic profiles of avian pathogenic and commensalMicrobial genomics · 2026Article
- Yad fimbriae are triggered by host cues and enhance extraintestinal pathogenic Escherichia coli tissue colonisation during bloodstream infection.PLoS pathogens · 2026Article
- Deciphering the Implications ofPathogens (Basel, Switzerland) · 2026Review
- Phylogenetic Groups, Virulence Factors, and Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2026Article
- Conjugation as an evolutionary bottleneck in antimicrobial resistance spread.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Plasmids are major vehicles for the spread of antibiotic resistance genes. Some plasmids additionally carry virulence genes that enhance host pathogenicity. The convergence of resistance and virulence genes on the same plasmid poses significant risk, providing a mechanism to create pathogens that cause severe disease with limited treatment options. Colicin V (ColV)-like plasmids (ColVLPs) are virulence plasmids frequently carried by extra-intestinal pathogenic E. coli (ExPEC) that cause human and avian infection. Here, by generating and analysing a ColVLP database, we demonstrate that ColVLPs form four distinct sub-groups, characterised by genes encoding for Colicins V and M, with differing virulence and antimicrobial resistance gene carriage. Three of these sub-groups possess moderate-high resistance towards multiple antibiotic classes. We further describe ColVLP co-integrates that have acquired extensive resistance profiles, including against last line colistin, through recombination with co-resident plasmids. Using pMS7163A, a ColVLP from a virulent ExPEC strain, we also demonstrate that the ColVLP-encoded outer membrane protease virulence factor OmpTp works co-operatively with its chromosomal homolog to enhance ExPEC resistance against human cathelicidin (LL-37), an antimicrobial peptide expressed in the urinary tract. Together, our work characterises ColVLPs as high-risk mobile genetic elements that amplify the convergence of resistance and virulence in ExPEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.